Next Generation Biomanufacturing Market Research Report By Technology (Synthetic Biology, Cell-Free Systems, Microbial Biomanufacturing, Continuous Bioprocessing), By Application (Pharmaceuticals, Food and Beverage, Biofuels, Bioplastics), By End Use (Industrial, Research and Development, Commercial), By Product Type (Enzymes, Amino Acids, Vaccines, Biopharmaceuticals) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa)- Forecast to 2035

Global Next Generation Biomanufacturing Market Overview

As per MRFR analysis, the Next Generation Biomanufacturing Market Size was estimated at 5.46 (USD Billion) in 2023.The Next Generation Biomanufacturing Market Industry is expected to grow from 5.83(USD Billion) in 2024 to 12 (USD Billion) by 2035. The Next Generation Biomanufacturing Market CAGR (growth rate) is expected to be around 6.78% during the forecast period (2025 - 2035).

Key Next Generation Biomanufacturing Market Trends Highlighted

The Next Generation Biomanufacturing Market is observing notable shifts in the market owing to the heightened global focus on the adoption of sustainable and efficient manufacturing processes. An important factor propelling the market includes the sustainable shift on part of the industry as they make efforts towards reducing their carbon emissions and optimizing resource utilization. On the global front, there is support for green initiatives and regulations which in turn, helps biomanufacturing, thus improving the prospects for growth in this industry. 

There are new opportunities with the growing requirements for biologically based materials in the fabrication of drugs as well as in agriculture and food industries. Active investments from companies in research and development are considered to advance and improve biomanufacturing techniques, thereby developing greater opportunities for new products and expansion in the market.

The recent trend in biomanufacturing processes involves the use of new technologies like artificial intelligence and automation. This evolution of technology improves the production processes and reduces waste, thus helping achieve sustainability. There is also a rise in the number of public-private partnerships that accelerate the development of biomanufacturing technologies. The market is also experiencing a shift due to an increase in demand for customized medicine leading to therapeutics manufactured using advanced methods. The combination of innovative technology and sustainable measures creates an opportunity for global next generation biomanufacturing to improve diverse industries while balancing regulatory requirements, and consumer and market demands.

The rapidly evolving world clearly demonstrates how biomanufacturing might be utilized as a solution to global health, environmental, and resource challenges.

Next Generation Biomanufacturing Market Drivers

Increasing Demand for Sustainable Production Processes

The Next Generation Biomanufacturing Market Industry is witnessing a substantial push towards sustainability as industries seek to minimize their ecological footprint. This shift is driven by consumer demand for environmentally friendly products, with recent reports indicating that 66% of global consumers are willing to pay more for sustainable brands. Major organizations like the World Economic Forum advocate for sustainable practices, thereby accelerating investments in biomanufacturing technologies. 

As countries worldwide enforce stricter environmental regulations, such as the European Union's Green Deal committing to climate neutrality by 2050, companies are incentivized to adopt next-generation biomanufacturing methods. This ensures compatibility not only with consumer expectations but also compliance with governmental policies aimed at reducing greenhouse gas emissions, thus boosting market growth significantly.

Advancements in Genetic Engineering Technologies

The Next Generation Biomanufacturing Market Industry is being propelled by rapid advancements in genetic engineering techniques such as CRISPR-Cas9. According to the National Institutes of Health, the market for gene editing is projected to expand by nearly 25% annually over the next five years, pinpointing its pivotal role in manufacturing biological products. Leading firms, such as Thermo Fisher Scientific, have made significant investments in genetic engineering tools that enhance productivity and efficacy in biomanufacturing.These advancements not only streamline the production of bio-based materials but also optimize the development of pharmaceuticals, thus expanding the overall market scope by introducing innovative solutions that meet global health demands.

Rising Focus on Biotechnology in Drug Development

The Next Generation Biomanufacturing Market Industry is significantly influenced by an increasing focus on biopharmaceuticals as a major avenue for drug development. In recent years, biopharmaceuticals have seen a consistent rise, accounting for over 33% of the pharmaceutical market in some regions as reported by the Biopharmaceutical Innovation Fund. 

Companies like Amgen and Genentech are at the forefront, investing heavily in biomanufacturing processes to accelerate the creation of biologics and monoclonal antibodies.With the growing prevalence of chronic diseases and an aging population worldwide, the demand for innovative treatments is expected to escalate, poised to further enhance the market dynamics over the coming decade.

Next Generation Biomanufacturing Market Segment Insights

Next Generation Biomanufacturing Market Technology Insights

The Next Generation Biomanufacturing Market, focusing on the Technology segment, is poised for significant growth and evolution in the coming years, driven by innovations and advancements across various technologies. In 2024, the Technology segment of the market showcased a diverse portfolio, comprising key areas such as Synthetic Biology, Cell-Free Systems, Microbial Biomanufacturing, and Continuous Bioprocessing. The Synthetic Biology sector leads the group with a valuation of 2.2 USD Billion in 2024, projected to more than double to 4.5 USD Billion by 2035, representing a majority holding and underscoring its critical role in developing engineered biological systems for various applications, including pharmaceuticals and biofuels.

Following closely, the Microbial Biomanufacturing sector is valued at 1.8 USD Billion in 2024 and is anticipated to reach 3.6 USD Billion by 2035, showcasing its significance in harnessing microorganisms for efficient production processes which facilitate sustainable manufacturing methods. The Cell-Free Systems technology, which was valued at 1.4 USD Billion in 2024, is also expected to expand to 2.8 USD Billion by 2035, signifying its growing importance in synthesizing biological components without the need for living cells, thereby enhancing efficiency and flexibility in production.

Lastly, Continuous Bioprocessing, with a smaller valuation of 0.43 USD Billion in 2024, is estimated to advance to 0.9 USD Billion by 2035, representing a niche yet vital aspect of the market that focuses on streamlining production processes, offering scalability and improved control. Overall, the diverse insights within this Technology segment signify not only a robust growth trajectory but also highlight the increasing demand for innovative biomanufacturing solutions that address both economic and environmental challenges globally. 

The collective data emphasizes a market that is evolving rapidly to meet industry needs and adapt to emerging trends, positioning itself well within the broader context of the Next Generation Biomanufacturing Market revenue and statistics.

Next Generation Biomanufacturing Market Application Insights

The Next Generation Biomanufacturing Market reached a value of USD 5.83 Billion in 2024, showcasing the continuing expansion of this industry. A significant part of this market is attributed to its Applications, which are crucial for advancing multiple sectors. The Pharmaceuticals segment plays an essential role by enabling the production of innovative therapies, thereby enhancing healthcare solutions globally. The Food and Beverage Application supports sustainable practices, reflecting a growing demand for natural ingredients that align with consumer preferences for healthy products.

Furthermore, the Biofuels segment is essential as it contributes to renewable energy initiatives that combat climate change. The Bioplastics Application is gaining prominence as environmentally-friendly alternatives to conventional plastics. This growing awareness of sustainability drives interest in the biomanufacturing space, indicating opportunities for future expansion. 

Overall, the diversity within the Next Generation Biomanufacturing Market highlights various growth drivers while addressing potential challenges, such as regulatory hurdles and technological advancements, ultimately contributing to market growth in the coming years.

Next Generation Biomanufacturing Market End Use Insights

The Next Generation Biomanufacturing Market achieved a valuation of 5.83 USD Billion in 2024, reflecting the growing significance of the End Use segment, which encompasses key areas such as Industrial, Research and Development, and Commercial applications. The Industrial sector is essential as it drives efficiency and sustainability in manufacturing processes, leveraging biotechnological advancements to produce bio-based products. Research and Development plays a crucial role in this market by fostering innovation and paving the way for new technologies, ultimately enhancing productivity and application scope.

Furthermore, the Commercial aspect is vital for transitioning research breakthroughs into marketable products, thereby meeting consumer demand and driving economic growth. The increasing need for sustainable manufacturing practices and the shift towards green technologies are significant growth drivers propelling the Next Generation Biomanufacturing Market forward. As stakeholders focus on improving operational efficiency and reducing environmental impact, the market is set to experience notable expansion. Overall, the market is characterized by robust activity across these key End Use areas, which are instrumental in shaping the future landscape of biomanufacturing globally.

Next Generation Biomanufacturing Market Product Type Insights

The Next Generation Biomanufacturing Market predominantly revolves around key product types including Enzymes, Amino Acids, Vaccines, and Biopharmaceuticals. In 2024, the market was valued at 5.83 billion USD, showcasing the robust demand for these components. Enzymes are pivotal in various bioprocesses, enhancing efficiency and sustainability, while Amino Acids serve as essential building blocks in pharmaceuticals and nutritional products, maintaining a substantial presence in the industry. Vaccines have been vital in public health, prompting advancements in biomanufacturing techniques to improve efficacy and safety.

Biopharmaceuticals continue to dominate due to their application in novel therapies and personalized medicine, reflecting the industry's response to the increasing prevalence of chronic diseases. The growth drivers for this market include technological advancements, a rising focus on sustainable practices, and increased investments in Research and Development. Meanwhile, challenges related to regulatory complexities and production scalability remain; however, the opportunities presented by emerging markets and innovations in synthetic biology are propelling the market forward.The Next Generation Biomanufacturing Market segmentation reveals a diverse and dynamic landscape influenced by these product types, which are shaping the future of biomanufacturing on a global scale.

Next Generation Biomanufacturing Market Regional Insights

The Next Generation Biomanufacturing Market is poised for significant growth across various regions, with a total valuation of 5.83 USD Billion set for 2024 and expected to reach 12.0 USD Billion by 2035. North America leads this market with a valuation of 2.3 USD Billion in 2024, capturing a majority holding due to its robust biotechnology infrastructure and extensive Research and Development initiatives. Europe follows closely, valued at 1.55 USD Billion in 2024, where strong regulatory support drives innovation in biomanufacturing processes.The Asia-Pacific (APAC) region, valued at 1.5 USD Billion, presents itself as a growing hub for biomanufacturing, supported by increasing investments in biopharmaceuticals. 

South America and the Middle East and Africa (MEA) represent smaller, yet emerging markets, valued at 0.25 USD Billion and 0.23 USD Billion, respectively in 2024, where expanding healthcare sectors offer opportunities for growth despite facing challenges such as regulatory hurdles. The overall Next Generation Biomanufacturing Market data shows a favorable competitive landscape with regional segmentation enhancing the market's global footprint and aligning with local health needs.

Next Generation Biomanufacturing Market Key Players and Competitive Insights

The competitive insights of the Next Generation Biomanufacturing Market reveal a landscape characterized by technological advancements, strategic collaborations, and increasing investments aimed at enhancing production processes for biologics. This market is witnessing a surge in demand for more efficient, cost-effective, and sustainable manufacturing methods in the biotechnology and pharmaceutical sectors. As organizations strive to optimize production capabilities while ensuring regulatory compliance and quality assurance, they are heavily focused on adopting innovative biomanufacturing technologies. 

Overall, the competition is shaped by factors such as the growing prevalence of chronic diseases, the need for personalized medicines, and advancements in synthetic biology that drive players to improve their manufacturing agility and capabilities.Lonza stands out prominently in the Next Generation Biomanufacturing Market due to its robust expertise in custom development and manufacturing for biological products. The company has a solid global presence, bolstered by extensive facilities strategically located in different regions, which enables it to cater to a diverse clientele efficiently. 

Lonza's strengths lie in its advanced bioprocessing technologies, including its well-regarded platforms for the cell and gene therapy manufacturing. Furthermore, the company maintains its competitive edge by fostering strong partnerships and collaborations that enhance its service offerings. Through continuous innovation and investment in cutting-edge manufacturing facilities, Lonza reinforces its commitment to meeting evolving market demands and producing high-quality biopharmaceutical products that are vital to the industry's growth.

Pfizer operates as a significant player in the Next Generation Biomanufacturing Market, featuring a comprehensive portfolio of biopharmaceutical solutions. The company has a strong market presence with state-of-the-art manufacturing capabilities that support the production of complex biologics, including monoclonal antibodies and advanced therapies. Pfizer's strengths are primarily demonstrated through its strategic investment in biomanufacturing and ongoing initiatives aimed at enhancing production efficiency, scalability, and regulatory compliance. The company has engaged in several mergers and acquisitions to bolster its capabilities and expand its technological expertise in biomanufacturing. 

By leveraging its extensive research and development resources, Pfizer continues to innovate its product lineup and maintain leadership in this competitive market, ultimately delivering valuable biotherapeutic solutions that cater to unmet medical needs on a global scale.

Key Companies in the Next Generation Biomanufacturing Market Include:

• Lonza


• Pfizer


• SABIC


• Thermo Fisher Scientific


• Ginkgo Bioworks


• AbbVie


• Merck KGaA


• Boehringer Ingelheim


• Zymeworks


• Codexis


• Corteva Agriscience


• Novartis


• Genomatica


• Evonik Industries


• Amgen

Next Generation Biomanufacturing Market Industry Developments

The Next Generation Biomanufacturing Market has seen significant developments recently. Notably, companies like Pfizer and Novartis are enhancing their biomanufacturing capabilities as they aim to meet the rising demand for biologics and precision medicine. In September 2023, Lonza announced a partnership with Ginkgo Bioworks to focus on bioproduction systems that leverage synthetic biology for sustainable manufacturing processes. 

Meanwhile, in August 2023, Merck KGaA expanded its manufacturing footprint by acquiring a facility from a competitor, enhancing their biopharmaceutical production capacity. The market is growing, with companies like Amgen and Thermo Fisher Scientific investing heavily in advanced technologies and Research and Development. Additionally, Boehringer Ingelheim has reported an increase in market valuation due to increased demand for their biosimilars. 

Over the past two years, there has been a notable trend of mergers and acquisitions among these companies aimed at increasing competitive advantage, reducing costs, and improving product quality. The ongoing advancements in automated manufacturing processes have also propelled growth in the sector, underscoring the importance of innovation and collaboration among industry players.

Next Generation Biomanufacturing Market Segmentation Insights

• 
  Next Generation Biomanufacturing Market Technology Outlook
  
  
  
  • Synthetic Biology
  
  
  • Cell-Free Systems
  
  
  • Microbial Biomanufacturing
  
  
  • Continuous Bioprocessing
  
  
  
  


• 
  Next Generation Biomanufacturing Market Application Outlook
  
  
  
  • Pharmaceuticals
  
  
  • Food and Beverage
  
  
  • Biofuels
  
  
  • Bioplastics
  
  
  
  


• 
  Next Generation Biomanufacturing Market End Use Outlook
  
  
  
  • Industrial
  
  
  • Research and Development
  
  
  • Commercial
  
  
  
  


• 
  Next Generation Biomanufacturing Market Product Type Outlook
  
  
  
  • Enzymes
  
  
  • Amino Acids
  
  
  • Vaccines
  
  
  • Biopharmaceuticals
  
  
  
  


• 
  Next Generation Biomanufacturing Market Regional Outlook
  
  
  
  • North America
  
  
  • Europe
  
  
  • South America
  
  
  • Asia Pacific
  
  
  • Middle East and Africa
  
  
  
  

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	5.46(USD Billion)
MARKET SIZE 2024	5.83(USD Billion)
MARKET SIZE 2035	12.0(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	6.78% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	Lonza, Pfizer, SABIC, Thermo Fisher Scientific, Ginkgo Bioworks, AbbVie, Merck KGaA, Boehringer Ingelheim, Zymeworks, Codexis, Corteva Agriscience, Novartis, Genomatica, Evonik Industries, Amgen
SEGMENTS COVERED	Technology, Application, End Use, Product Type, Regional
KEY MARKET OPPORTUNITIES	Sustainable production methods, Advanced cell culture technologies, Integration of AI and IoT, Expansion in personalized medicine, Bioprocess optimization solutions
KEY MARKET DYNAMICS	Technological advancements, Sustainability initiatives, Regulatory support, Increased investment, Growing demand for biopharmaceuticals
COUNTRIES COVERED	North America, Europe, APAC, South America, MEA